Diseases

Camizestrant (Etcamah) gains accelerated FDA approval for ESR1-mutated advanced breast cancer, with median progression-free survival of 16 months versus 9.2 months in SERENA-6. #SyenzaNews #BreastCancer #FDA #Oncology

South Africa has initiated 55,123 people on twice-yearly lenacapavir PrEP in the programme's first 94 days. Demand is strongest in Gauteng and KwaZulu-Natal; branded supply, second-dose retention and the 2027 generic tender are the real constraints. #SyenzaNews #HIVPrevention #Lenacapavir #MarketAccess

Novartis and The Max Foundation mark 25 years of partnership that has delivered cancer treatment to more than 100,000 patients across 71 LMICs. The next test is whether the model can carry a broader oncology portfolio and transition to country funding. #SyenzaNews #MarketAccess #GlobalHealth

An Insilico Medicine phase 2a trial found six proteomic aging clocks all detected lower biological age in patients treated with rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis. #SyenzaNews #Proteomics #AgingClocks #DrugDiscovery #IPF

Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA

Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck's once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess

Aspen Pharmacare posted 22% normalised earnings growth and is betting on a manufacturing rebound and a generic semaglutide rollout for FY2027. #SyenzaNews #Pharma #GLP1 #MarketAccess #SouthAfrica

US Medicare is paying for obesity GLP-1s for the first time, and more than 500,000 seniors signed up in the first two months. Our latest breaks down the $245 price, the $50 copay, and what it means for Lilly and Novo Nordisk. #SyenzaNews #MarketAccess #GLP1 #Medicare

Novartis and Bristol Myers Squibb have paused autoimmune CAR-T trials after inflammatory events and three deaths, putting the immune-reset thesis to its first real safety test. #SyenzaNews #CellTherapy #AutoimmuneDisease #MarketAccess

The RECOVER-VITAL trial found nirmatrelvir-ritonavir offered no benefit for long COVID across cognitive, autonomic, or exercise symptoms. The study also shows why placebo controls matter: a large share of the placebo group improved on their own. #SyenzaNews #LongCOVID #ClinicalTrials #MarketAccess

Novartis' oral BTK inhibitor remibrutinib met its primary endpoint in the Phase III REMODEL-1 and REMODEL-2 trials, cutting annualized relapse rates versus teriflunomide in relapsing multiple sclerosis. #SyenzaNews #MultipleSclerosis #MarketAccess #Neurology

Cipla has licensed Sino Biopharm's HER2 biparatopic ADC TQB2102 for India, South Africa and five other emerging markets. The deal caps at USD 123 million plus double-digit royalties, with access to HER2-low breast cancer as the core case. #SyenzaNews #Oncology #MarketAccess #DrugDevelopment